Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sensus Healthcare, Inc. (SRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

BOCA RATON, Fla. , April 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host First Quarter 2021 Financial Results and Business Update Conference Call on May 6, 2021

Sensus Healthcare stock fell to lows of $1.9 during 2020, from highs of >$9 in mid-2019, owing to a pandemic-induced collapse in annual sales from $27.3m to $9.6m in FY20. The company has developed Superficial Radiation Technology ("SRT") to treat oncological and non-oncological skin conditions, including keloid scarring.

Sensus Healthcare: Likely Post-Pandemic Sales Recovery Can Boost Share Price

BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a  medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that Joe Sardano, Chairman and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:

Sensus Healthcare to Participate in Three Investment Conferences During the Month of March

The stock price of Sensus Healthcare Inc (NASDAQ: SRTS) increased by 37.8% after hours as it went from a previous close of $3.81 to $5.25. This is why it happened.

SRTS Stock Price Increased 37.8% After Hours: Why It Happened

Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices Patent covers beam splitting and sculpting capabilities of radiation to treat all types of solid tumors with Sculptura™ and potentially other devices

Sensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source

BOCA RATON, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced Holy Name Medical Center in Teaneck, New Jersey has acquired a Sensus low-dose radiation therapy system for the treatment of pneumonia in COVID-19 patients.

Holy Name Medical Center in Teaneck, New Jersey Acquires Sensus Healthcare's Low-dose Radiation Therapy System to Treat Pneumonia in COVID-19 Patients

Sensus Healthcare' (SRTS) CEO Joe Sardano on Q3 2020 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

Sensus Healthcare Reports Third Quarter 2020 Financial Results

BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Megan Cornish to its board of directors, effective January 1, 2021. Ms. Cornish's appointment will expand the number of directors to six.

Sensus Healthcare Appoints Megan Cornish to its Board of Directors

BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020

Sensus Healthcare' (SRTS) CEO Joe Sardano on Q2 2020 Results - Earnings Call Transcript

Sensus Healthcare Reports Second Quarter 2020 Financial Results

Beginning September 1, Category A credits will be available for in-person trainings on the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems

American Society of Radiologic Technologists Approves Sensus Healthcare’s SRT Systems for Continuing Education Units

Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state

Sensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida

﻿BOCA RATON, Fla. , July  30, 2020  (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2020. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020

BOCA RATON, Fla. , July  28, 2020  (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales.  Mr. Suen will focus on sales of the Company’s Superficial Radiation Therapy (SRT) products across Southeast Asia and will report directly to Joe Sardano, chief executive officer.  The Company is also announcing the resumption of shipments to China with the sale of an SRT-100™ system, a direct result of Mr. Suen’s efforts.

Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China

BOCA RATON, Fla., July  13, 2020  (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19  webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.

Sensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th

BOCA RATON, Fla. , June  30, 2020  (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Joe Sardano, the company’s chief executive officer, will participate in a panel discussion today at the Fall Clinical Virtual Grand Rounds Weekly Continuing Education Series. The program, titled “Directions in Dermatology and Their Impact on You: Patients, Practice and Pharma,” is part of the recent online series titled “Evolving Concepts in Dermatology;   Dermatology Industry Leaders   :   The Path Forward.”

Sensus Healthcare’s CEO to Participate in Dermatology Practice Panel Discussion as Part of the Fall Clinical Virtual Grand Rounds Weekly Series

BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Jeffrey S. Fromowitz, M.D. will discuss the use of superficial radiation therapy at the Fall Clinical Virtual Grand Rounds Weekly Continuing Education Series today.

Sensus Healthcare Announces CME Presentation by Dr. Jeffrey S.

June 18 Event is the Third in a Series of Topical Discussions

Sensus Healthcare and David Goldberg, M.D., J.D. to Host a Virtual Program on Dermatology Medical and Legal Issues in the Era of COVID-19

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2020 Results - Earnings Call Transcript

Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT

Sensus Healthcare Announces Publication of Research on Long-term Efficacy and Safety of Superficial Radiation Therapy in Journal of Drugs in Dermatology

Sensus Healthcare's (SRTS) CEO Joe Sardano on Q4 2019 Results - Earnings Call Transcript

BOCA RATON, Fla, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce it has shipped and installed a Sculptura™ radiation oncology system to Stanford Health Care in Palo Alto, Calif.  The system was shipped in December.  This is the third system to be shipped by Sensus and follows the sale of one system to Beilinson Hospital of the Rabin Medical Center in Israel and one to the University of Pennsylvania in Philadelphia. Sculptura received U.S. Food and Drug Administration 510(k) clearance in February 2019. 

News for Sensus Healthcare Stock (SRTS)